CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
Panitumumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00630786
NCT00630786Phase 2Completed
CompareCT.gov

A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer

Amgen·interventional·Posted Mar 7, 2008·Updated Feb 6, 2014

In Brief

A Phase 2 clinical trial evaluating Panitumumab and Conatumumab for Colon Cancer and 4 related conditions. Completed, enrolled 53 participants.

Detailed Summary

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer, Oncology
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartJan 1, 2008
Primary CompletionMay 1, 2009
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.3 years ago

Interventions

Panitumumabdrug

Administered by intravenous infusion

Conatumumabdrug

Administered by intravenous infusion